SPOTLAB SL

Their core work

SPOTLAB SL is a Madrid-based deep-tech SME developing portable, AI-powered image diagnostic devices that transform ordinary smartphones into clinical-grade diagnostic tools. Their core product combines smartphone optics, 3D-printed hardware accessories, and machine learning algorithms to enable point-of-care microscopy and image-based diagnosis without expensive laboratory equipment. They followed a textbook SME Instrument path: a Phase 1 feasibility study (MicroSpot) validated the concept of a robotized smartphone scanner microscope, and a Phase 2 project (SpotLab) funded the full commercial development. Their target is to make immediate, affordable diagnostic imaging available anywhere — clinics, field settings, or resource-limited environments.

What they specialise in

How they've shifted over time

SPOTLAB's H2020 trajectory is a tightly focused two-step commercialization sequence rather than a shift in domain. In 2018, their work centered on proving the hardware concept — a robotized, low-cost smartphone microscope (MicroSpot). By 2019, the focus expanded significantly to incorporate AI and 3D printing, moving from a single-function microscope toward a platform for ubiquitous image-based diagnosis (SpotLab). The evolution is one of increasing technical ambition and market scope, not a pivot — they deepened and broadened the same core idea rather than changing direction.

SPOTLAB is moving toward a full-stack diagnostic platform combining hardware, AI software, and scalable manufacturing — likely positioning for medtech or global health markets where affordable diagnostics are a pressing need.

How they like to work

SPOTLAB operates exclusively as a project coordinator and, unusually, with no registered consortium partners in either project — suggesting they executed both grants as a solo company or with subcontractors not captured in the CORDIS partner data. This points to a highly self-contained team that prefers to own and control the full development process. For future collaborators, this means SPOTLAB is more likely to lead a consortium than join one as a contributor, and may be selective about partnerships that directly complement gaps in their technology stack.

CORDIS records show zero registered consortium partners across both projects, which is atypical and likely reflects the solo SME Instrument structure where subcontractors are used rather than formal consortium members. Their formal European research network appears undeveloped, making them an open partner for organizations seeking a technology provider with a validated product concept.

What sets them apart

SPOTLAB occupies a specific niche at the intersection of consumer smartphone hardware, AI diagnostics, and 3D manufacturing — a combination that is rare among European medtech SMEs. They have successfully secured both phases of the SME Instrument, which signals that their business case and technology readiness were evaluated as credible by EU reviewers. For a consortium needing a point-of-care diagnostics technology partner with a product that is past concept stage and into commercialization, SPOTLAB offers a validated, fundable proposition.

Highlights from their portfolio

• SpotLab
  The flagship Phase 2 SME Instrument grant of €1.57M funded full commercialization of an AI + smartphone + 3D printing diagnostic platform — the largest and most technically ambitious project in their portfolio.
• MicroSpot
  The Phase 1 feasibility study that validated the core concept of a portable robotized smartphone microscope, directly enabling the larger SpotLab grant and demonstrating a disciplined product development pathway.